You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on breast cancer.
A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and were associated with lower response to aromatase inhibitors.
Results of the randomized Phase III BROCADE trial, recently published in The Lancet Oncology, suggested a benefit of veliparib combined with platinum-based chemotherapy.
In the dose expansion portion of the trial, CFI-402257 will be evaluated in three arms, including estrogen receptor-positive, HER2-negative breast cancer, TNBC, and solid tumor patients.
The trial will use Natera's Signatera test to determine patient enrollment eligibility based on the presence of ctDNA and to evaluate response based on ctDNA clearance.
The Phase II IRENE study will evaluate a virus-based treatment with an anti-PD1 checkpoint inhibitor in patients with triple-negative breast cancer.
Using MammaPrint to guide breast cancer chemo de-escalation could result in significant healthcare savings in five of six evaluated countries, according to the analysis.
The firm said its genetic tests for breast, prostate, and colorectal cancers and melanoma assess a patient's personal cancer risks and guide personalized prevention.
The drugmaker said it is working with centers of excellence in Canada to set up companion diagnostic testing to identify patients with PIK3CA mutations.
Tumor microenvironment cell transcriptomes pointed to four stromal cell clusters, including immune interacting support cells predicted to impact immunotherapy response.
Patients on the combo regimen had similar outcomes to those on monotherapy, but researchers said that the benefit seen in certain groups should be explored in randomized trials.